Shape Memory Medical Announces Publication of Study Results in Vascular

2023-05-30

上市批准

SANTA CLARA, Calif.--(BUSINESS WIRE)--Shape Memory Medical Inc., developer of shape memory polymer for peripheral and neurovascular markets, announced the publication of results from the Company’s prospective, open-label, single-arm, safety study of the IMPEDE Embolization Plug in peripheral vascular embolization. The study was published this month in the peer-reviewed journal, Vascular, ahead of print.

'We look forward to seeing how shape memory polymer in clinical practice continues to evolve.'

Ted Ruppel, Chief Executive Officer of Shape Memory Medical Inc. said, "We would like to congratulate the investigators and clinical research team at Auckland City Hospital for completing the study and retrospective review of follow-up imaging. The publication is a significant milestone for the Company as we continue to evaluate the potential of shape memory polymer and specifically the IMPEDE Embolization Plug family in a variety of arterial and venous applications.”

Both the IMPEDE and IMPEDE-FX Embolization Plugs incorporate shape memory polymer (“smart” polymer), a porous, radiolucent, embolic scaffold that is crimped for catheter delivery and self-expands upon contact with blood for acute thrombosis and occlusion. The material is highly conformable and able to accommodate irregular surfaces with low chronic outward force. Shape memory polymer has also been shown in pre-clinical studies to be fully bioresorbable, over time, with collagen formation and fibrosis and without chronic inflammation.

The safety study was registered with the Australian New Zealand Clinical Trials Registry (ANZCTR): 12617000906358. Procedures were performed from August 2017 through December 2019. Embolized peripheral vascular vessels include inferior mesenteric arteries, testicular veins to treat varicoceles, internal iliac, renal accessory, and left subclavian arteries to treat or prevent endoleaks, and a profunda branch prior to tumor resection and hemiarthroplasty. Acute technical success of target vessel embolization was achieved in all implantation cases, and no serious adverse events related to the study device occurred. No recurrent clinical symptoms attributable to treated vessel embolization or recanalization were documented through 30-day follow-up.

A retrospective review of follow-up imaging through a mean of 22.2 months (range,

“Shape memory polymer technology in peripheral vascular embolization” was first published online in Vascular on May 22, 2023 and is available via open access.

About Shape Memory Medical

Shape Memory Medical Inc. is dedicated to developing innovative therapeutic solutions with its proprietary shape memory polymers. Neurovascular embolization products include the TrelliX® Embolic Coil, which is CE marked for use in the EU. Peripheral embolization products include the IMPEDE® and IMPEDE-FX Embolization Plugs and IMPEDE-FX RapidFill® Device. In countries recognizing CE marking, the IMPEDE and IMPEDE-FX Embolization Plugs and the IMPEDE-FX RapidFill are indicated to obstruct or reduce the rate of blood flow in the peripheral vasculature. In the United States, the IMPEDE Embolization Plug is indicated to obstruct or reduce the rate of blood flow in the peripheral vasculature, and the IMPEDE-FX Embolization Plug is indicated for use with the IMPEDE Embolization Plug to obstruct or reduce the rate of blood flow in the peripheral vasculature. The IMPEDE and IMPEDE-FX Embolization Plugs are PMDA approved in Japan. The TrelliX Embolic Coil and IMPEDE-FX RapidFill Device are not available in the United States or Japan.

For more information, visit www.shapemem.com.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构